Compare INVZ & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVZ | KLRS |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | Israel | United States |
| Employees | 415 | 20 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.1M | 132.8M |
| IPO Year | N/A | N/A |
| Metric | INVZ | KLRS |
|---|---|---|
| Price | $0.69 | $6.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $3.10 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 2.7M | 63.7K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.61 | N/A |
| Revenue Next Year | $53.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $2.14 |
| 52 Week High | $2.54 | $11.88 |
| Indicator | INVZ | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 39.66 |
| Support Level | $0.58 | $4.35 |
| Resistance Level | $1.03 | $7.20 |
| Average True Range (ATR) | 0.05 | 0.63 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 78.59 | 53.16 |
Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.